The U.S. Food and Drug Administration has approved Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) as the first gene therapy for the treatment of children with metachromatic leukodystrophy (MLD).
This article was originally published on MedicalXpress.com